Regentis Biomaterials (NYSE American: RGNT) announced that it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process. This milestone supports the product's planned commercial launch in Europe. The new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
To view the full press release, visit https://ibn.fm/Ths4h. The latest news and updates relating to RGNT are available in the company's newsroom at https://ibn.fm/RGNT.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
This approval is significant as it paves the way for scaled-up manufacturing and commercial availability of GelrinC in Europe, addressing a large unmet need for cartilage repair. The improved manufacturing process not only boosts yield but also enhances safety and environmental sustainability, aligning with broader industry trends. With the U.S. cartilage repair market valued at $3 billion and no off-the-shelf treatment currently available, Regentis is well-positioned to capture significant market share upon eventual FDA approval. The company's partnerships with leading orthopedic institutions further strengthen its commercialization strategy.
